News about "Samsung Biologics"

Samsung Biologics to Acquire PolyPeptide in All-Cash Deal

Samsung Biologics has launched a CHF 1.46 billion all-cash offer to acquire PolyPeptide, expanding its global CDMO network and multi-modality strategy.

Samsung Biologics | 23/07/2026 | By News Bureau |  112

Samsung Biologics Expands into US with GSK Facility Acquisition in Maryland

Samsung Biologics has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland from GSK, marking its first manufacturing presence in the United States.

Samsung Biologics | 02/04/2026 | By Darshana |  173

Samsung Biologics Expands US Manufacturing with HGS Acquisition from GSK

Samsung Biologics has acquired Human Genome Sciences (HGS) from GSK, securing its first US-based manufacturing site and strengthening its global supply network. The company plans further investments to expand capacity and capabilities at the facility, reinforcing its long-term commitment to the US biopharmaceutical manufacturing ecosystem.

Samsung Biologics | 22/12/2025 | By News Bureau |  354

Samsung Biologics Launches ExellenS Framework to Standardize and Accelerate Biomanufacturing Operations

By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.

Samsung Biologics | 10/10/2025 | By Dineshwori |  357

Samsung Biologics Reports Robust Q2 FY2025 Results, Driven by Full Plant Utilisation and New Offerings

Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.

Samsung Biologics | 23/07/2025 | By Dineshwori |  1542

Samsung Biologics Announces Manufacturing Deal with European Pharmaceutical Company

Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.

Samsung Biologics | 20/11/2024 | By Aishwarya |  431

Samsung Biologics Secures ISO Certifications for its Business Excellence

The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.

Samsung Biologics | 11/11/2024 | By Aishwarya |  670

Samsung Biologics Inks Manufacturing Deal with Asian Pharmaceutical Company

With the latest agreement, the company's accumulated contract for 2024 surpasses USD 3.3 billion.

Samsung Biologics | 22/10/2024 | By Aishwarya |  671

Samsung Biologics Develops High-Concentration Formulation Platform for Drug Development

S-HiCon can proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery.

Samsung Biologics | 15/10/2024 | By Aishwarya |  614

Samsung Biologics Introduces Development Platforms for Enhanced Therapeutic Efficacy

Samsung Biologics has unveiled a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.<br />

Samsung Biologics | 26/09/2024 | By Aishwarya |  574